Formula: C1105H1770N318O336S26

Summary Information: FERTIGYN HP is a medication containing human chorionic gonadotropin (HCG) as the active pharmaceutical ingredient. It is a hormone that plays a crucial role in various reproductive processes. FERTIGYN HP is primarily used in the treatment of infertility, particularly in women undergoing assisted reproductive techniques such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Product Composition: FERTIGYN HP contains human chorionic gonadotropin (HCG) as the active ingredient. HCG is a glycoprotein hormone produced during pregnancy, primarily by the placenta. It mimics the action of luteinizing hormone (LH) and is involved in the maturation and release of eggs from the ovaries in women. Each vial of FERTIGYN HP is formulated with a specific concentration of HCG for use in fertility treatments.

Manufacturer: FERTIGYN HP may be manufactured by various pharmaceutical companies, and the specific manufacturer should be indicated on the packaging or accompanying documentation.

Package: FERTIGYN HP is typically available in the form of vials containing lyophilized (freeze-dried) powder for reconstitution. The vials may vary in size and may contain a specific dosage of HCG, as prescribed by a healthcare professional.

Usage Instructions: FERTIGYN HP is administered via intramuscular or subcutaneous injection, as directed by a healthcare provider. The powder in the vial is reconstituted with a suitable solvent (usually sterile water) before administration. The dosage and timing of injections are tailored to each individual’s treatment protocol, and it is essential to follow the instructions provided by the healthcare provider closely.

Storage: FERTIGYN HP should be stored according to the manufacturer’s instructions. Generally, it should be kept at controlled room temperature, protected from light and moisture. Once reconstituted, any unused portion should be discarded according to proper disposal guidelines.

Caution:

• FERTIGYN HP should only be used under the supervision of a qualified healthcare professional experienced in fertility treatments.
• It is important to perform appropriate monitoring and follow-up during treatment with FERTIGYN HP to assess its efficacy and adjust the treatment protocol as needed.
• Women undergoing treatment with FERTIGYN HP should be monitored for ovarian hyperstimulation syndrome (OHSS) and other potential side effects.

Precautions and Contraindications:

• FERTIGYN HP is contraindicated in individuals with known hypersensitivity to HCG or any of the components of the product.
• It should not be used in women with certain medical conditions such as hormone-sensitive cancers or ovarian cysts.
• Use in pregnant women or nursing mothers should be avoided unless specifically prescribed for medical reasons.

FERTIGYN HP plays a crucial role in fertility treatments, particularly in triggering ovulation and supporting the development of follicles during assisted reproductive techniques. It is an essential component of many infertility treatment protocols and offers hope to individuals and couples seeking to conceive. However, its use should always be guided by a healthcare professional specializing in reproductive medicine.